| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.EJCA.2017.08.025 |
| P698 | PubMed publication ID | 28950146 |
| P50 | author | Jihane Pakradouni | Q57338645 |
| Jean-Marie Boher | Q59200097 | ||
| Keyvan Rezai | Q60619173 | ||
| Renaud Sabatier | Q82068977 | ||
| Magali Provansal | Q112902541 | ||
| P2093 | author name string | Emmanuelle Charafe-Jauffret | |
| Mario Campone | |||
| Patrice Viens | |||
| François Bertucci | |||
| Nicolas Isambert | |||
| François Lokiec | |||
| Mathilde Guerin | |||
| Anthony Gonçalves | |||
| Alice Hervieu | |||
| Jean-Marc Extra | |||
| Aurélie Autret | |||
| Jacques Camerlo | |||
| P304 | page(s) | 28-36 | |
| P577 | publication date | 2017-09-23 | |
| P1433 | published in | European Journal of Cancer | Q332260 |
| P1476 | title | PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer | |
| P478 | volume | 86 |
| Q49886531 | A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer |
| Q92143284 | Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors |
| Q58554058 | Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer |
| Q92143276 | Efficacy of PI3K inhibitors in advanced breast cancer |
| Q47676373 | Everolimus induced mood changes in breast cancer patients: a case-control study. |
| Q59795283 | Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review |
| Q49478004 | Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date |
| Q55353691 | Recent Advances in the Treatment of Breast Cancer. |
| Q49887919 | Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors |
| Q64119664 | Targeting stem cells in the realm of drug-resistant breast cancer |
| Q55435506 | The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment. |
Search more.